Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma

Ramanjit Sihota, Rohit Saxena, H. C. Agarwal, Vikas Gulati

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Objective: To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy. Methods: We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug. Results: The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P=.01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients taking latanoprost and 26 (43%) on timolol achieved a reduction of more than 30% from baseline IOP. Conclusion: There were greater mean and peak IOP reductions achieved with 0.005% latanoprost once daily compared with 0.5% timolol twice daily.

Original languageEnglish (US)
Pages (from-to)185-189
Number of pages5
JournalArchives of Ophthalmology
Issue number2
StatePublished - Feb 2004
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma'. Together they form a unique fingerprint.

Cite this